These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31745600)

  • 1. Acute porphyrias: a German monocentric study of the biochemical, molecular genetic, and clinical data of 62 families.
    Bronisch O; Stauch T; Haverkamp T; Beykirch MK; Petrides PE
    Ann Hematol; 2019 Dec; 98(12):2683-2691. PubMed ID: 31745600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical and financial burden of acute intermittent porphyria.
    Neeleman RA; Wagenmakers MAEM; Koole-Lesuis RH; Mijnhout GS; Wilson JHP; Friesema ECH; Langendonk JG
    J Inherit Metab Dis; 2018 Sep; 41(5):809-817. PubMed ID: 29675607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetrance and predictive value of genetic screening in acute porphyria.
    Baumann K; Kauppinen R
    Mol Genet Metab; 2020 May; 130(1):87-99. PubMed ID: 32067921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute attacks of hepatic porphyria: specific treatment with heme arginate].
    Nordmann Y; Deybach JC
    Ann Med Interne (Paris); 1993; 144(3):165-7. PubMed ID: 8368699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium.
    Bonkovsky HL; Maddukuri VC; Yazici C; Anderson KE; Bissell DM; Bloomer JR; Phillips JD; Naik H; Peter I; Baillargeon G; Bossi K; Gandolfo L; Light C; Bishop D; Desnick RJ
    Am J Med; 2014 Dec; 127(12):1233-41. PubMed ID: 25016127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity.
    Hift RJ; Meissner PN
    Medicine (Baltimore); 2005 Jan; 84(1):48-60. PubMed ID: 15643299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early administration of heme arginate for acute porphyric attacks.
    Mustajoki P; Nordmann Y
    Arch Intern Med; 1993 Sep; 153(17):2004-8. PubMed ID: 8357285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Porphyrias.
    Besur S; Schmeltzer P; Bonkovsky HL
    J Emerg Med; 2015 Sep; 49(3):305-12. PubMed ID: 26159905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute porphyrias - A neurological perspective.
    Gerischer LM; Scheibe F; Nümann A; Köhnlein M; Stölzel U; Meisel A
    Brain Behav; 2021 Nov; 11(11):e2389. PubMed ID: 34661997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute porphyrias in the Argentinean population: a review.
    Parera VE; De Siervi A; Varela L; Rossetti MV; Batlle AM
    Cell Mol Biol (Noisy-le-grand); 2003 Jun; 49(4):493-500. PubMed ID: 12899439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurovisceral porphyrias: what a hematologist needs to know.
    Bonkovsky HL
    Hematology Am Soc Hematol Educ Program; 2005; ():24-30. PubMed ID: 16304355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of inherited porphyrias in Europe.
    Elder G; Harper P; Badminton M; Sandberg S; Deybach JC
    J Inherit Metab Dis; 2013 Sep; 36(5):849-57. PubMed ID: 23114748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health impact of acute intermittent porphyria in latent and non-recurrent attacks patients.
    Buendía-Martínez J; Barreda-Sánchez M; Rodríguez-Peña L; Ballesta-Martínez MJ; López-González V; Sánchez-Soler MJ; Serrano-Antón AT; Pérez-Tomás ME; Gil-Ferrer R; Avilés-Plaza F; Glover-López G; Carazo-Díaz C; Guillén-Navarro E
    Orphanet J Rare Dis; 2021 Feb; 16(1):106. PubMed ID: 33639982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of porphyrias in Italy: a diagnostic flow-chart.
    Martinez di Montemuros F; Di Pierro E; Patti E; Tavazzi D; Danielli MG; Biolcati G; Rocchi E; Cappellini MD
    Cell Mol Biol (Noisy-le-grand); 2002 Dec; 48(8):867-76. PubMed ID: 12699245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of acute porphyrias. The importance of follow-up of patients and carriers].
    Tasnádi G; Bor M; Pusztai A
    Orv Hetil; 2003 May; 144(19):933-8. PubMed ID: 12809070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the Patient-Reported Outcomes Measurement Information System scales in acute intermittent porphyria.
    Naik H; Overbey JR; Montgomery GH; Winkel G; Balwani M; Anderson KE; Bissell DM; Bonkovsky HL; Phillips JD; Wang B; McGuire B; Keel S; Levy C; Erwin A; Desnick RJ
    Genet Med; 2020 Mar; 22(3):590-597. PubMed ID: 31690837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E; Harper P; Andersson DE; Floderus Y
    Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best practice guidelines on clinical management of acute attacks of porphyria and their complications.
    Stein P; Badminton M; Barth J; Rees D; Stewart MF;
    Ann Clin Biochem; 2013 May; 50(Pt 3):217-23. PubMed ID: 23605132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Porphyrias-what is verified?].
    Stölzel U; Kubisch I; Stauch T
    Internist (Berl); 2018 Dec; 59(12):1239-1248. PubMed ID: 30328490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A family with acute intermittent porphyria.
    Billoo AG; Lone SW
    J Coll Physicians Surg Pak; 2008 May; 18(5):316-8. PubMed ID: 18541093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.